Sagimet enters global exclusive license with TAPI for innovative resmetirom API for FDC program

Sagimet Biosciences Inc.

License grants Sagimet exclusive global rights to TAPI's innovative forms of resmetirom API for fixed-dose combination with denifanstat.
Sagimet paid $2.5M upfront; TAPI may receive low single-digit royalties and up to $5.5M in manufacturing milestones.
Phase 1 PK trial of denifanstat + resmetirom underway; topline data expected by end of 2025.
Sagimet plans to select one TAPI resmetirom form for a single FDC tablet for Phase 3 study in H2 2026.
Combination targets MASH cirrhosis (F4) where no approved therapies exist.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.